Sirnaomics Ltd. (02257.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.8x

Market Cap

HKD 358.95M

MomentumView details →

1D Return

−3.55%

YTD Return

−50.46%

RSI (14)

42.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.8x

Market Cap

HKD 358.95M

RSI (14)

42.6

MomentumView details →

1D Return

−3.55%

YTD Return

−50.46%

ProfitabilityView details →

Gross Margin

−124.51%

Net Margin

−2597.52%

EBITDA Margin

−2937.32%

ROE (TTM)

406.56%

ROA (TTM)

−183.75%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

−27.39%

EPS YoY

+98.27%

FCF YoY

+86.05%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+77.27%

EBITDA YoY

+97.98%

EarningsView details →

EPS (Actual)

HKD 0.01

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−4.17x

Current Ratio

0.26x

Quick Ratio

0.26x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

949000.00

Net Income (TTM)

−24.65M

Op. CF (TTM)

−18.36M

Next earningsApr 1, 2027 →

Latest newsMore news →

Sirnaomics announced that its indirect non-wholly owned subsidiary RNAimmune will introduce Guangzhou Guangjian Pharmaceutical Innovation Equity Investment Fund Partnership as a strategic investor, injecting RMB 30 million into Damian Vaccine (Guangzhou) for a 5.66% stake.9d ago

Sirnaomics Ltd and its wholly-owned subsidiary Sirnaomics (Hong Kong) Limited filed a writ of summons in the High Court of the Hong Kong Special Administrative Region against several former management members, including Lu Yang, Dai Xiaochang, and Ye Yongji, over an investment of approximately US$20 million in an independent portfolio of TradArt Flagship Investment SPC.19d ago

Similar companies

Uni-Bio Science Group Limited00690.HK Q32 Bio Inc.QTTB DiaMedica Therapeutics Inc.DMAC Palisade Bio, Inc.PALI Lyell Immunopharma, Inc.LYEL Alpha Tau Medical Ltd.DRTSW Find similar companies →

Latest newsMore news →

Sirnaomics announced that its indirect non-wholly owned subsidiary RNAimmune will introduce Guangzhou Guangjian Pharmaceutical Innovation Equity Investment Fund Partnership as a strategic investor, injecting RMB 30 million into Damian Vaccine (Guangzhou) for a 5.66% stake.9d ago Sirnaomics Ltd and its wholly-owned subsidiary Sirnaomics (Hong Kong) Limited filed a writ of summons in the High Court of the Hong Kong Special Administrative Region against several former management members, including Lu Yang, Dai Xiaochang, and Ye Yongji, over an investment of approximately US$20 million in an independent portfolio of TradArt Flagship Investment SPC.19d ago